1.����ҩ�ƴ�ѧ������ѧ��������ҩѧԺ,���� 110032�� 2.�й������ž���ҽԺ, a. ҩ��/��е�ٴ���������, b. ������; c. ҩ�Ĵ�,���� 100853
In Vitro Activity of Colistin Combination with Fosfomycin Against Klebsiella pneumoniae Carbapenemase-producing K. pneumonia
HE Ji-tong1,2b, TAO Jing2a, NI Wen-tao2b, WANG Jin2a, WANG Rui2a, ZHANG Yong2c*
1. Department of Life Science and Biological Pharmaceutical, Shenyang Pharmaceutical University, Shenyang 110032, China; 2a. Center of Medicine/Medical Devices Clinical Research; 2b. Department of Respiratory Diseases, 2c. Department of Pharmacy Chinese People��s Liberation Army General Hospital, Beijing 100853, China
Abstract��OBJECTIVE To evaluate the antibacterial effects of colistin combined with fosfomycin against Klebsiella pneumoniae carbapenemase-producing K. pneumonia in vitro. METHODS The minimal inhibitory concentration(MIC) of colistin and fosfomycin against 74 strains of KPC-Kp was determined by agar dilution method and broth microdilution method respectively.The fractional inhibitory concentration index( FICI )was calculated by checkerboard method to determine the combined effect.SixKPC-Kp strains were randomly selected to determine the time-killing curves of colistin and fosfomycin alone or in combination. RESULTS The MIC results: polymyxin sensitivity rate of 100%, fosfomycin sensitivity rate of 35.14%.The FIC results: In 74 strains,12.16% synergism, 39.19% section synergism,6.76% additive effect,41.89% irrelevant,no antagonism found.The results of time-kill assay showed that there was a significant synergistic effect between colistin and fosfomycin in fosfomycin-sensitive strains, while fosfomycin-resistant strains showed no synergistic effect. CONCLUSION In the case of fosfomycin-sensitive strains, the combination of colistin and fosfomycin has synergistic effects on KPC-Kp in vitro, and time-kill assay also shows a good synergistic effect. Resistant strains are poor in synergism.
�ؼ�ͯ,�վ�,������,���,���,����. ������E������ù�ضԲ�̼��ùϩø�����ײ��������⿹�������о�[J]. �й�ҩѧ��־, 2017, 52(13): 1132-1136.
HE Ji-tong, TAO Jing, NI Wen-tao, WANG Jin, WANG Rui, ZHANG Yong. In Vitro Activity of Colistin Combination with Fosfomycin Against Klebsiella pneumoniae Carbapenemase-producing K. pneumonia. Chinese Pharmaceutical Journal, 2017, 52(13): 1132-1136.
WEI Z Q, DU X X, YU Y S, et al. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrob Agents Chemother, 2007, 51(2):763-765.
[2]
CARSS. National report on bacterial drug resistance surveillance in 2015 http://www.carss.cn.
[3]
NORDMANN P, CUZON G, NAAS T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis, 2009, 9(4):228-236.
[4]
CHINESE XDR CONSENSUS WORKING GROUP. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. Clin Microbiol Infect, 2016,22(suppl 1):15-25.
[5]
WIKLER M A. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement. Wayne:Clinical and Laboratory Standards Institute, 2006.
[6]
CLINICAL AND LABORATORY STANDARDS INSTITUTE. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. Approved standard M100-S23. Wayne:Clinical and Laboratory Standards Institute, 2013.
[7]
PFAUSLER B, SPISS H, DITTRICH, et al. Concentrations of fosfomycin in the cerebrospinalfluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother, 2004, 53:848-852.
[8]
GARONZIK S M, LI J, THAMLIKITKUL, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother, 2011, 55:3284-3294.
[9]
PLACHOUR A S, KARVANEN D, FRIBERG M, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother, 2009, 53:3430-3436. BERGEN P J, BULMAN Z P, SAJU S, et al. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy, 2015, 35(1):34-42. ENDIMIANI A, PATEL G, HUJER K M, et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsuscepti ble to tigecycline and/or colistin. Antimicrob Agents Chemother, 2010, 54(1):526-529. DI X, WANG R, LIU B, et al. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa. J Antibiot(Tokyo), 2015, 68(9):551-555. SOULI M, GALANI I, BOUKOVALAS S, et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother, 2011, 55(5):2395-2397. SAMONIS G, MARAKI S, KARAGEORGOPOULOS D E, et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis, 2012, 31(5):695-701.
2017, Vol. 52 
